Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Avenciguat by Boehringer Ingelheim International for Chronic Kidney Disease (Chronic Renal Failure): Likelihood of Approval
Avenciguat is under clinical development by Boehringer Ingelheim International and currently in Phase II for Chronic Kidney Disease (Chronic Renal...
BI-690517 by Boehringer Ingelheim International for Chronic Kidney Disease (Chronic Renal Failure): Likelihood of Approval
BI-690517 is under clinical development by Boehringer Ingelheim International and currently in Phase II for Chronic Kidney Disease (Chronic Renal...
Ezabenlimab by Boehringer Ingelheim International for Hepatocellular Carcinoma: Likelihood of Approval
Ezabenlimab is under clinical development by Boehringer Ingelheim International and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData,...
BI-1821736 by Boehringer Ingelheim International for Solid Tumor: Likelihood of Approval
BI-1821736 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Solid Tumor. According to GlobalData,...
Ezabenlimab by Boehringer Ingelheim International for Oral Cavity (Mouth) Cancer: Likelihood of Approval
Ezabenlimab is under clinical development by Boehringer Ingelheim International and currently in Phase I for Oral Cavity (Mouth) Cancer. According...
Ofev by Boehringer Ingelheim International for Lymphangioleiomyomatosis: Likelihood of Approval
Ofev is under clinical development by Boehringer Ingelheim International and currently in Phase II for Lymphangioleiomyomatosis. According to GlobalData, Phase...
BI-765423 by Boehringer Ingelheim International for Pulmonary Fibrosis: Likelihood of Approval
BI-765423 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Pulmonary Fibrosis. According to GlobalData,...
BI-764532 by Boehringer Ingelheim International for Neuroendocrine Carcinoma: Likelihood of Approval
BI-764532 is under clinical development by Boehringer Ingelheim International and currently in Phase II for Neuroendocrine Carcinoma. According to GlobalData,...
BI-764532 by Boehringer Ingelheim International for Small-Cell Lung Cancer: Likelihood of Approval
BI-764532 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Small-Cell Lung Cancer. According to...
BI-1387446 by Boehringer Ingelheim International for Solid Tumor: Likelihood of Approval
BI-1387446 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Solid Tumor. According to GlobalData,...
Empagliflozin by Boehringer Ingelheim International for Renal Stones/Calculi: Likelihood of Approval
Empagliflozin is under clinical development by Boehringer Ingelheim International and currently in Phase II for Renal Stones/Calculi. According to GlobalData,...
BI-764532 by Boehringer Ingelheim International for Glioma: Likelihood of Approval
BI-764532 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Glioma. According to GlobalData, Phase...
BI-764532 by Boehringer Ingelheim International for Neuroendocrine Cancer: Likelihood of Approval
BI-764532 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Neuroendocrine Cancer. According to GlobalData,...
Zongertinib by Boehringer Ingelheim International for Esophageal Cancer: Likelihood of Approval
Zongertinib is under clinical development by Boehringer Ingelheim International and currently in Phase I for Esophageal Cancer. According to GlobalData,...
Zongertinib by Boehringer Ingelheim International for Colorectal Cancer: Likelihood of Approval
Zongertinib is under clinical development by Boehringer Ingelheim International and currently in Phase I for Colorectal Cancer. According to GlobalData,...
BI-905711 by Boehringer Ingelheim International for Metastatic Colorectal Cancer: Likelihood of Approval
BI-905711 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Metastatic Colorectal Cancer. According to...
BI-905711 by Boehringer Ingelheim International for Esophageal Cancer: Likelihood of Approval
BI-905711 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Esophageal Cancer. According to GlobalData,...
BI-905711 by Boehringer Ingelheim International for Gastric Cancer: Likelihood of Approval
BI-905711 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Gastric Cancer. According to GlobalData,...
Afatinib dimaleate by Boehringer Ingelheim International for Refractory Multiple Myeloma: Likelihood of Approval
Afatinib dimaleate is under clinical development by Boehringer Ingelheim International and currently in Phase II for Refractory Multiple Myeloma. According...
Zongertinib by Boehringer Ingelheim International for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Zongertinib is under clinical development by Boehringer Ingelheim International and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According...